|
| 37131619 | Interplay between and mutations governs innate immune responses in diffuse gliomas. | | 2023 |
| 37760589 | Repurposing Clemastine to Target Glioblastoma Cell Stemness. | Cancers (Basel) | 2023 |
| 36639156 | Tacedinaline (CI-994), a class I HDAC inhibitor, targets intrinsic tumor growth and leptomeningeal dissemination in MYC-driven medulloblastoma while making them susceptible to anti-CD47-induced macrophage phagocytosis via NF-kB-TGM2 driven tumor inflammation. | J Immunother Cancer | 2023 |
| 35324138 | Cold Plasma Discharge Tube Enhances Antitumoral Efficacy of Temozolomide. | ACS Applied Bio Materials | 2022 |
| 35247901 | Antitumor Activity of a Mitochondrial-Targeted HSP90 Inhibitor in Gliomas. | Clin Cancer Res | 2022 |
| 34593527 | A Modified Nucleoside 6-Thio-2'-Deoxyguanosine Exhibits Antitumor Activity in Gliomas. | Clin Cancer Res | 2021 |
| 31040154 | MTAP Loss Promotes Stemness in Glioblastoma and Confers Unique Susceptibility to Purine Starvation. | Cancer Research | 2019 |
| 30625226 | Synergistic antitumor effects of 9.2.27-PE38KDEL and ABT-737 in primary and metastatic brain tumors. | PLoS ONE | 2019 |
| 29703821 | A Rationally Designed Fully Human EGFRvIII:CD3-Targeted Bispecific Antibody Redirects Human T Cells to Treat Patient-derived Intracerebral Malignant Glioma. | Clinical Cancer Research | 2018 |
| 30266879 | Correction: Reversing the Warburg effect as a treatment for glioblastoma. | Journal of Biological Chemistry | 2018 |
| 30120661 | Bevacizumab, irinotecan, temozolomide, tyrosine kinase inhibition, and MEK inhibition are effective against pleomorphic xanthoastrocytoma regardless of V600E status. | Journal of Neuro-Oncology | 2018 |
| 29564747 | Sym004-induced EGFR elimination is associated with profound anti-tumor activity in EGFRvIII patient-derived glioblastoma models. | Journal of Neuro-Oncology | 2018 |
| 29258295 | Therapeutic targeting of ependymoma as informed by oncogenic enhancer profiling. | Nature | 2018 |
| 27786412 | Initial testing of VS-4718, a novel inhibitor of focal adhesion kinase (FAK), against pediatric tumor models by the Pediatric Preclinical Testing Program. | Pediatr Blood Cancer | 2017 |
| 28379574 | The role of angiogenesis in Group 3 medulloblastoma pathogenesis and survival. | Neuro Oncol | 2017 |
| 28669010 | A cross sectional analysis from a single institution's experience of psychosocial distress and health-related quality of life in the primary brain tumor population. | Journal of Neuro-Oncology | 2017 |
| 28829151 | Validation of an Immunohistochemistry Assay for Detection of CD155, the Poliovirus Receptor, in Malignant Gliomas. | | 2017 |
| 27650817 | Initial testing (stage 1) of the curaxin CBL0137 by the pediatric preclinical testing program. | Pediatr Blood Cancer | 2017 |
| 27496711 | Evaluation of Alternative In Vivo Drug Screening Methodology: A Single Mouse Analysis. | Cancer Res | 2016 |
| 27238606 | Initial Testing (Stage 1) of MK-8242-A Novel MDM2 Inhibitor-by the Pediatric Preclinical Testing Program. | Pediatr Blood Cancer | 2016 |
| 26797892 | Initial Testing of NSC 750854, a Novel Purine Analog, Against Pediatric Tumor Models by the Pediatric Preclinical Testing Program. | Pediatr Blood Cancer | 2016 |
| 27160908 | A Therapeutic Antibody for Cancer, Derived from Single Human B Cells. | Cell Rep | 2016 |
| 26766590 | MiR-215 Is Induced Post-transcriptionally via HIF-Drosha Complex and Mediates Glioma-Initiating Cell Adaptation to Hypoxia by Targeting KDM1B. | Cancer Cell | 2016 |
| 26398108 | Pharmacodynamic and genomic markers associated with response to the XPO1/CRM1 inhibitor selinexor (KPT-330): A report from the pediatric preclinical testing program. | Pediatr Blood Cancer | 2016 |
| 25986925 | Dynamic treatment effect (DTE) curves reveal the mode of action for standard and experimental cancer therapies. | Oncotarget | 2015 |
| 25500058 | Synergistic activity of PARP inhibition by talazoparib (BMN 673) with temozolomide in pediatric cancer models in the pediatric preclinical testing program. | Clin Cancer Res | 2015 |
| 25407467 | Initial testing (stage 1) of BAL101553, a novel tubulin binding agent, by the pediatric preclinical testing program. | Pediatr Blood Cancer | 2015 |
| 25263539 | Initial testing (stage 1) of the PARP inhibitor BMN 673 by the pediatric preclinical testing program: PALB2 mutation predicts exceptional in vivo response to BMN 673. | Pediatr Blood Cancer | 2015 |
| 25598002 | Proteomic profiling of patient-derived glioblastoma xenografts identifies a subset with activated EGFR: implications for drug development. | J Neurochem | 2015 |
| 26429914 | Phosphorylation of Glutathione S-Transferase P1 (GSTP1) by Epidermal Growth Factor Receptor (EGFR) Promotes Formation of the GSTP1-c-Jun N-terminal kinase (JNK) Complex and Suppresses JNK Downstream Signaling and Apoptosis in Brain Tumor Cells. | Journal of Biological Chemistry | 2015 |
| 25115740 | Profiling Hsp90 differential expression and the molecular effects of the Hsp90 inhibitor IPI-504 in high-grade glioma models. | Journal of Neuro-Oncology | 2014 |
| 23956067 | Initial testing (stage 1) of the Polo-like kinase inhibitor volasertib (BI 6727), by the Pediatric Preclinical Testing Program. | Pediatr Blood Cancer | 2014 |
| 24038993 | Initial testing (stage 1) of the histone deacetylase inhibitor, quisinostat (JNJ-26481585), by the Pediatric Preclinical Testing Program. | Pediatr Blood Cancer | 2014 |
| 24722048 | Mutations in IDH1, IDH2, and in the TERT promoter define clinically distinct subgroups of adult malignant gliomas. | Oncotarget | 2014 |
| 25202981 | miR-33a promotes glioma-initiating cell self-renewal via PKA and NOTCH pathways. | Journal of Clinical Investigation | 2014 |
| 24623675 | Initial testing (stage 1) of the investigational mTOR kinase inhibitor MLN0128 by the pediatric preclinical testing program. | Pediatr Blood Cancer | 2014 |
| 24664981 | Initial testing (stage 1) of the notch inhibitor PF-03084014, by the pediatric preclinical testing program. | Pediatr Blood Cancer | 2014 |
| 25131802 | Initial solid tumor testing (stage 1) of AZD1480, an inhibitor of Janus kinases 1 and 2 by the pediatric preclinical testing program. | Pediatr Blood Cancer | 2014 |
| 23115013 | Recombinant anti-podoplanin (NZ-1) immunotoxin for the treatment of malignant brain tumors. | International Journal of Cancer | 2013 |
| 22753001 | Initial testing of the MDM2 inhibitor RG7112 by the Pediatric Preclinical Testing Program. | Pediatr Blood Cancer | 2013 |
| 23002019 | Initial testing (stage 1) of the phosphatidylinositol 3' kinase inhibitor, SAR245408 (XL147) by the pediatric preclinical testing program. | Pediatr Blood Cancer | 2013 |
| 23857604 | Construction of an immunotoxin, D2C7-(scdsFv)-PE38KDEL, targeting EGFRwt and EGFRvIII for brain tumor therapy. | Clinical Cancer Research | 2013 |
| 23798344 | Initial testing (Stage 1) of the antibody-maytansinoid conjugate, IMGN901 (Lorvotuzumab mertansine), by the pediatric preclinical testing program. | Pediatr Blood Cancer | 2013 |
| 24240169 | KMT2D maintains neoplastic cell proliferation and global histone H3 lysine 4 monomethylation. | Oncotarget | 2013 |
| 23924792 | Affinity-matured recombinant immunotoxin targeting gangliosides 3'-isoLM1 and 3',6'-isoLD1 on malignant gliomas. | mAbs | 2013 |
| 24093630 | Proteasome inhibition with bortezomib induces cell death in GBM stem-like cells and temozolomide-resistant glioma cell lines, but stimulates GBM stem-like cells' VEGF production and angiogenesis. | Journal of Neurosurgery | 2013 |
| 23917401 | The integrated landscape of driver genomic alterations in glioblastoma. | Nat Genet | 2013 |
| 23592488 | Exomic sequencing of four rare central nervous system tumor types. | Oncotarget | 2013 |
| 23303741 | Initial testing (stage 1) of ganetespib, an Hsp90 inhibitor, by the Pediatric Preclinical Testing Program. | Pediatr Blood Cancer | 2013 |
| 23553917 | Initial testing (stage 1) of eribulin, a novel tubulin binding agent, by the pediatric preclinical testing program. | Pediatr Blood Cancer | 2013 |